AI assistant
Sending…
Teva Pharmaceutical Industries Ltd. — Earnings Release 2004
Nov 4, 2004
7082_rns_2004-11-04_5e7ad9ed-dab0-4120-9d1c-8d59f3345847.htm
Earnings Release
Open in viewerOpens in your device viewer
| C001 | טבע תעשיות פרמצבטיות בע"מ | 2 | |
| Public | TEVA- PHARMACEUTICAL INDUSTRIES LTD. | ||
| 2529 | Corporation no: 520013954 | ||
| Stock Exchange/Market: טבע | |||
| 310 | |||
| 379 | P.O.B 3190 , Petach Tikva 49131 , , | ||
| Tel: 03-9267297 , 03-9267281 Fax: 03-9267429 | |||
| E.mail address: [email protected] | Date of transmission: 04/11/2004 | ||
| Time of broadcast: 13:27 11:05:36 | |||
| Reference: 2004-02-124809 | |||
| Israel Securities Authority | Tel Aviv Stock Exchange | |||||
| www.isa.gov.il | www.tase.co.il |
Report of Periodic or Interim ReportRegulation 3 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000
| The corporation is a foreign private issuer as defined by U.S. Securities Laws. |
| Attached hereto is a report on |
| TEVA REPORTS RECORD Q3 SALES, NET INCOME, EPS AND CASH FLOW |
| Q3-04-final041104united_isa.pdf |
| Please find attached a press release and its non-binding hebrew translation, provided for convenience purposes only |
| References of previous documents relating to this matter(the reference does not constitute incorporation by reference): |
| Previous name of reporting entity: |
| Date of revision of form structure: 08/09/2004 |
| - - - |
| Name of the Signatory : Suesskind Dan Position of Signatory in the reporting corporation: Chief Financial Officer |
| Basel Telephone: 02-5892840 , Facsimile: 02-5892839 , E-mail: [email protected] |
More from Teva Pharmaceutical Industries Ltd.
Declaration of Voting Results & Voting Rights Announcements
2026
May 28
Declaration of Voting Results & Voting Rights Announcements
2026
May 28
Regulatory Filings
2026
May 28
Director's Dealing
2026
May 18
Director's Dealing
2026
May 18
Director's Dealing
2026
May 18
Director's Dealing
2026
May 18
Director's Dealing
2026
May 7
Director's Dealing
2026
May 7
Director's Dealing
2026
May 7